Neumora
Watertown, Massachusetts, United States · Biotechnology, Biotechnology Research, Health Care
Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options a
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Watertown, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Biotechnology Research, Health Care
- Status
- Public (NMRA)
- Website
- ir.neumoratx.com
- Company page
Recent activity at Neumora
- : Neumora Therapeutics Names Joshua Pinto, Ph.D. as Chief Executive Officer
- : SEC 8-K (5.02): On August 14, 2026, Neumora Therapeutics, Inc. announced a significant leadership transition where Paul L. Berns will step down as Chief Executive Officer and take on the role of Executive Chairperson. Joshua Pinto, Ph.D., currently the Company's President, will succeed Mr. Berns as Chief Executive Officer effective the same day. This transition was approved by the Board on August 12, 2026, and Dr. Pinto was also appointed as a Class III director with a term expiring at the 2029 Annual Meeting of Stockholders. This change signifies a strategic shift in leadership and continuity as Dr. Pinto retains his position as President.
- : SEC 8-K (8.01): On July 27, 2026, Neumora Therapeutics, Inc. announced favorable pre-clinical toxicology results from NMRA-215 through a press release. This development may significantly impact the company’s research trajectory and strategic positioning within the pharmaceutical industry, indicating progress in their drug development pipeline. The press release is included as Exhibit 99.1 of the Form 8-K, highlighting the importance of these results to stakeholders. The release and subsequent filing serve to inform investors and analysts of the positive steps being taken towards potential future revenues from NMRA-215.
About Neumora: questions and answers
What does Neumora do?
Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options a
Where is Neumora headquartered?
Neumora is headquartered in Watertown, Massachusetts, United States.
What is the latest news on Neumora?
On Aug 14, 2026, Neumora Therapeutics Names Joshua Pinto, Ph.D. as Chief Executive Officer
Is Neumora a public company?
Yes. Neumora is publicly traded under the ticker NMRA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy